Who is sponsoring SELECT-AXIS 1?

SELECT-AXIS 1 is sponsored by AbbVie.

What condition does SELECT-AXIS 1 study?

SELECT-AXIS 1 studies Ankylosing Spondylitis (AS).

What drugs are being tested in SELECT-AXIS 1?

Interventions: Upadacitinib, Placebo.

What is the status of SELECT-AXIS 1?

SELECT-AXIS 1 is currently COMPLETED.

Last reviewed 2023-03-07 · How we verify

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis (SELECT-AXIS 1)

NCT03178487 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).

Details

Lead sponsor	AbbVie
Phase	PHASE2
Status	COMPLETED
Enrolment	187
Start date	Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Feb 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Ankylosing Spondylitis (AS)

Interventions

Upadacitinib
Placebo

Countries

Italy, Finland, Japan, Poland, South Korea, Croatia, Denmark, New Zealand, Netherlands, Belgium, Sweden, Portugal, United States, France, Hungary, Canada, Spain, United Kingdom, Germany, Australia, Czechia